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A B S T R A C T
Background
Pancreas or kidney-pancreas transplantation improves survival and quality of life for people with type 1 diabetes mellitus and kidney
failure. Immunosuppression aDer transplantation is associated with complications. Steroids have adverse eLects on cardiovascular
risk factors such as hypertension, hyperglycaemia or hyperlipidaemia, increase risk of infection, obesity, cataracts, myopathy, bone
metabolism alterations, dermatologic problems and cushingoid appearance. Whether avoiding steroids changes outcomes is unclear.
Objectives
We aimed to assess the safety and eLicacy of steroid early withdrawal (treatment for less than 14 days aDer transplantation), late
withdrawal (aDer 14 days aDer transplantation) or steroid avoidance in patients receiving a pancreas (including a vascularized organ) alone
(PTA), simultaneous with a kidney (SPK) or aDer kidney transplantation (PAK).
Search methods
We searched the Cochrane Renal Group's Specialised Register (to 18 June 2014) through contact with the Trials' Search Co-ordinator. We
handsearched: reference lists of nephrology textbooks, relevant studies, recent publications and clinical practice guidelines; abstracts from
international transplantation society scientific meetings; and sent emails and letters seeking information about unpublished or incomplete
studies to known investigators.
Selection criteria
We included randomised controlled trials (RCTs) or cohort studies of steroid avoidance (including early withdrawal) versus steroid
maintenance or versus late withdrawal in pancreas or pancreas with kidney transplant recipients. We defined steroid avoidance
as complete avoidance of steroid immunosuppression, early steroid withdrawal as steroid treatment for less than 14 days aDer
transplantation and late withdrawal as steroid withdrawal aDer 14 days aDer transplantation.
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Data collection and analysis
Two authors independently assessed the retrieved titles and abstracts, and where necessary the full text reports to determine which
studies satisfied the inclusion criteria. Authors of included studies were contacted to obtain missing information. Statistical analyses were
performed using random eLects models and results expressed as risk ratio (RR) or mean diLerence (MD) with 95% confidence interval (CI).
Cohort studies were not meta-analysed, but their findings summarised descriptively.
Main results
Three RCTs enrolling 144 participants met our inclusion criteria. Two compared steroid avoidance versus late steroid withdrawal and one
compared late steroid withdrawal versus steroid maintenance. All studies included SPK and only one also included PTA. All studies had
an overall moderate risk of bias and presented only short-term results (six to 12 months). Two studies (89 participants) compared steroid
avoidance or early steroid withdrawal versus late steroid withdrawal. There was no clear evidence of an impact on mortality (2 studies,
89 participants: RR 1.64, 95% CI 0.21 to 12.75), risk of kidney loss censored for death (2 studies, 89 participants: RR 0.35, 95% CI 0.04 to
3.09), risk of pancreas loss censored for death (2 studies, 89 participants: RR 1.05, 95% CI 0.36 to 3.04), or acute kidney rejection (1 study, 49
participants: RR 2.08, 95% CI 0.20 to 21.50), however results were uncertain and consistent with no diLerence or important benefit or harm
of steroid avoidance/early steroid withdrawal. The study that compared late steroid withdrawal versus steroid maintenance observed no
deaths, no graD loss or acute kidney rejection at six months in either group and reported uncertain eLects on acute pancreas rejection (RR
0.88, 95% CI 0.06 to 13.35). Of the possible adverse eLects only infection was reported by one study. There were significantly more UTIs
reported in the late withdrawal group compared to the steroid avoidance group (1 study, 25 patients: RR 0.41, 95% CI 0.26 to 0.66).
We also identified 13 cohort studies and one RCT which randomised tacrolimus versus cyclosporin. These studies in general showed
that steroid-sparing and withdrawal strategies had benefits in lowering HbAc1 and risk of infections (BK virus and CMV disease) and
improved blood pressure control without increasing the risk of rejection. However, two studies found an increased incidence of acute
pancreas rejection (HR 2.8, 95% CI 0.89 to 8.81, P = 0.066 in one study and 43.3% in the steroid withdrawal group versus 9.3% in the steroid
maintenance, P < 0.05 at three years in the other) and one study found an increased incidence of acute kidney rejection (18.7% in the
steroid withdrawal group versus 2.8% in the steroid maintenance, P < 0.05) at three years.
Authors' conclusions
There is currently insuLicient evidence for the benefits and harms of steroid withdrawal in pancreas transplantation in the three RCTs
(144 patients) identified. The results showed uncertain results for short-term risk of rejection, mortality, or graD survival in steroid-sparing
strategies in a very small number of patients over a short period of follow-up. Overall the data was sparse, so no firm conclusions are
possible. Moreover, the 13 observational studies findings generally concur with the evidence found in the RCTs.
P L A I N   L A N G U A G E   S U M M A R Y
Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients
People with type 1 diabetes and kidney failure have a poor survival. In the clinical course, they suLer from several diabetic vascular
complications and usually have progressive kidney impairment. Pancreas transplantation improves survival and quality of life and controls
blood glucose without the need for insulin therapy, making pancreas with kidney transplantation the treatment of choice in most
patients with type 1 insulin-dependent diabetes and kidney failure. More than 95% of transplant recipients are treated with steroids
as part of their immunosuppression. Steroid treatment has complications including: hypertension, hyperglycaemia or hyperlipidaemia,
increase risk of infection, obesity, cataracts, muscle disease, bone metabolism alterations and skin problems. However, without adequate
immunosuppression, transplant patients are at risk of transplant rejection and transplant failure. This review looked at two strategies -
steroid avoidance and steroid withdrawal - to investigate their impact on short- and long-term outcomes. These strategies could be used
in adults in the first few days aDer transplantation when used in combination with more powerful immunosuppressive agents. Twenty-one
studies were identified and evaluated in this review although only three RCTs enrolling 144 participants met our inclusion criteria. Steroid
avoidance and steroid withdrawal strategies in pancreas and pancreas with kidney transplantation were not apparently associated with
increased mortality, graD loss or acute rejection, although more studies are needed.
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B A C K G R O U N D
Description of the condition
Diabetes mellitus is a major health problem estimated to aLect
100 million people worldwide. Data from large epidemiologic
studies indicate that the incidence of type 1 diabetes has been
increasing at a rate of 3% to 5% per year. In the United States,
the prevalence of type 1 diabetes is 5399 cases in a population of
3.5 million (EURODIAB 2000; Karvonen 2000; Maahs 2010; SEARCH
2006). Diabetes mellitus is the leading single cause of end-stage
kidney disease (ESKD), accounting for approximately one third
of all new patients. The frequency of type 1 and 2 diabetes in
incident ESKD patients is diLerent depending on the country. Data
from 2009 shows an incidence of 17% in Norway, 25% in United
Kingdom and Spain, 30% in Australia, and 45% in the USA and
Japan (ANZDATA 2011; ERA-EDTA 2009; RMRC 2010; USRDS 2011). It
is undeniable that kidney transplantation is associated with better
results compared to dialysis techniques in terms of survival. Today,
one of the treatment possibilities for type 1 diabetes mellitus
is the whole vascularized pancreas transplant. Although there
are reports on successful simultaneous pancreas-kidney (SPK)
transplantation in patients with type 2 diabetes (not overweight),
there are limitations for the extension of this combined procedure
in this patient group (Morath 2009). Pancreas transplantation
was first used for the treatment of diabetes in humans in 1966
(Kelly 1967). In order to achieve normoglycaemia without the
administration of exogenous insulin, a pancreas transplant alone
(PTA) or an islet cell transplant before the development of a severe
kidney dysfunction is indicated. For patients who have already
developed ESKD, pancreas transplantation usually is performed
in combination with kidney transplantation to correct the kidney
dysfunction and the underlying metabolic disease.
Criteria for a patient considering PTA are based on a significantly
impaired quality of life and risk of death secondary to
hypoglycaemic unawareness, brittle diabetic control, and the
presence of early diabetic complications. Among patients who have
insulin-dependent diabetes mellitus and kidney disease, those
who have minimal or limited secondary diabetic complications
are considered the best candidates for SPK or pancreas aDer
kidney (PAK). These patients tend to be between 20 and 45 years
of age. ODen the patients’ decision to also undergo pancreas
transplantation is not diLicult, because they already require
lifelong immunosuppression as part of the medical regimen
following kidney transplantation. The decision of having both
organs transplanted simultaneously (SPK) or to undergo two
transplantations in sequence, with a period of recovery between,
is determined by whether the patient has a living kidney donor.
In general, the worst results in terms of graD survival are obtained
with deceased donor kidney transplantation. The longer time is
predicted to be in the waiting list, the better advantage of living
donor kidney transplantation compared to SPK is. If a PTA is
being done aDerwards, the superiority of living donor kidney
transplantation grows. During the period 2000 to 2007 in the
US, nearly 12,000 type 1 diabetic patients on the waiting list for
kidney and pancreas transplant received a first transplantation:
47% received a SPK, 29% a living donor kidney transplant and
a 24% a deceased donor kidney transplant (Poommipanit 2010).
Of the 3,461 who received a living donor kidney transplant, 807
(23%) received a pancreas alone aDer the kidney, and the remaining
patients (77%) did not. An analysis taking into account the
confounding factors was done showing that the five-year survival
PAK patient and kidney graD survival were significantly better than
those of the SPK recipient. On the other hand, pancreatic graD
survival was better with SPK than PTA. These diLerences remained
aDer censoring for death with functioning graD (Poommipanit
2010). Previous studies have already observed improved graD
survival in recipients receiving a living kidney transplant than SPK
(Young 2009), with similar survival of the patient.
ADer successful SPK, PAK or PTA, the majority of patients
achieve normoglycaemia and normal or nearly normal levels of
glycosylated haemoglobin (HbA1c), associated with an improved
quality of life (Morath 2008; Morath 2009). In patients with ESKD
and type 1 diabetes, it is not clear whether long-term kidney
allograD and patient survival in SPK recipients is superior to that of
recipients of a kidney transplant alone. A recent publication based
on the data of the Collaborative Transplant Study analysed graD
and patient survival in recipients who were treated with SPK or
PTA with a follow-up of 18 years, and found that glycaemic control
with a functioning pancreas allograD has a beneficial eLect on renal
allograD and patient survival (Morath 2008). They showed that aDer
10 years, patient survival in SPK transplantation was even better
than in recipients of a living donor kidney supported by a lower
rate of cardiovascular deaths in recipients of a combined organ
transplant. In recipients of single pancreas transplant, stabilization
or even regression of diabetic kidney and heart lesions have been
documented aDer the fiDh year of normoglycaemia (achieved by a
functioning allograD) (Fioretto 1998; Morath 2009).
Description of the intervention
The commonest immunosuppressive protocols in pancreas
transplantation include calcineurin inhibitors cyclosporin (CsA)
or tacrolimus (TAC), mTOR inhibitors or antimetabolites, steroids
and most centres also use induction with polyclonal or
monoclonal antibodies. Pancreas allograDs are particularly highly
immunogenic. Given the high incidence of immunologic graD loss
in pancreas transplant recipients, more than 95% of recipients
are treated with corticosteroids as a component of clinical
immunosuppressive regimens. In SPK cases, the most frequent
reason for late graD loss is death with a functioning graD and the
most frequent cause of death is cardiovascular disease (Sutherland
2006). Immunosuppressive drug protocols may have an impact in
cardiovascular morbidity and mortality in this population. They
are eLective in reducing the incidence of acute rejection but are
an important cause of morbidity and probably of mortality (Opelz
2005). The interest in steroid-sparing protocols has reappeared
with the introduction of new immunosuppressive agents. Although
previous studies, published in the 1980s and 1990s, showed that
even in immunologically low-risk selected transplant recipients,
prednisone withdrawal was associated with an increased risk of
acute rejection and graD loss (Matas 2005). The issue of steroid-
free regimens remains controversial, nevertheless the data suggest
that approximately 40% of pancreas transplant recipients are on
regimens that avoid steroids (Kandaswamy 2013).
How the intervention might work
Corticosteroids have harmful eLects on cardiovascular risk
factors such as hypertension, hyperglycaemia or hyperlipidaemia,
deleterious eLects on bone metabolism, increased risk of infection
(Matas 2005), obesity, cataracts, myopathy, dermatologic problems
and cushingoid appearance (Rajab 2007). Although nowadays it
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is a common practice in many centres removing kidney and
liver transplant recipients from steroids, in the case of pancreas
transplant recipients it has not been a routinely practice due
to the higher incidence of immunologic graD loss and the need
for more immunosuppression (Jepkorir 2012). Due to the fact
that the leading cause of post-transplant mortality in these
recipients is cardiovascular disease and given the association
between steroids and adverse eLects that are likely to increase
the risk of cardiovascular disease, this group of recipients
would definitely benefit from steroid sparing strategies. Thus,
finding an immunosuppressive regimen that provides suLicient
immunosuppression, whilst minimising the harmful side eLects, is
appealing to all involved in transplantation.
Clinicians have attempted to reduce the steroid doses used aDer
transplantation, and complete steroid avoidance or withdrawal
have been tested in a number of randomised controlled trials
(RCTs), in kidney transplantation, which have been systematically
reviewed in at least four reports. In the first systematic review of
prednisone withdrawal and avoidance published in 1993 (Hricik
1993) there were included three steroid withdrawal and four steroid
avoidance RCTs in a total of 1273 patients on CsA with or without
azathioprine (AZA) (681 in the steroid-free group and 592 in the
maintenance group) and they showed a high rate of acute rejection
aDer steroid withdrawal (incidence 48% in steroid-free versus 30%
in controls; P = 0.012), without proving any deleterious eLect on
graD survival. Similar results were found in the second review
published in 2000 (Kasiske 2000), which included 10 RCTs (eight
RCT were performed in patients receiving double therapy CsA
and steroids or triple therapy including AZA and only two RCTs
included patients receiving MMF). In this review, they showed a
significant increase in acute rejection (RR 0.14, 95% CI 0.10 to
0.17; P < 0.001) and a 40% increase in graD failure rates aDer
prednisone elimination (RR 1.40, 95% CI 1.09 to 1.70; P = 0.012).
The third meta-analysis of six RCTs of prednisone withdrawal
in kidney transplant patients on triple therapy with calcineurin
inhibitors and MMF also showed an increase in acute rejection (RR
2.28 (95% CI 1.65 to 3.16; P 0.00001) and no detectable impact
on early graD failure rate (RR 0.73; 95% CI 0.42 to 1.28; P 0.27)
(Pascual 2004). The last review published on this topic (Pascual
2009), which included 30 RCTs enrolling 5949 participants, reported
that steroid-sparing strategies were not associated with increased
mortality or graD loss despite an increase in acute rejection (RR
1.27, 95% CI 1.14 to 1.40). They concluded that steroid avoidance
or elimination a few days aDer kidney transplantation (PAK) was
safe if antibody induction treatment is prescribed, or aDer three to
six months if such induction is not used, and that it was associated
with benefits in reducing antihypertensive drug need, serum
cholesterol, antihyperlipidaemic drug need, new-onset diabetes
aDer transplantation, and cataracts.
Why it is important to do this review
Whilst the use of steroids in immunosuppression strategies has
been associated with excellent long-term outcomes specially
in terms of preventing rejection, it is also well known that
they have significant side eLects that cause significant harm
particularly in the diabetic recipients. The appearance of new
immunosuppressive drugs contributed to the practice of steroid-
sparing protocols in some transplant units without any evidence-
based recommendation announced and very few published studies
showing their results. Steroid sparing strategies in SPK, PAK or PTA
have been attempted in some RCTs, but these strategies have never
been systematically reviewed.
O B J E C T I V E S
We aimed to assess the safety and eLicacy of steroid early
withdrawal (treatment for less than 14 days aDer transplantation),
late withdrawal (aDer 14 days aDer transplantation) or steroid
avoidance in patients receiving a PTA (including a vascularized
organ), SPK or PAK.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Inclusion criteria• RCTs or quasi-RCTs (RCTs in which allocation to treatment was
obtained by alternation, use of alternate medical records, date
of birth or other predictable methods) of steroid avoidance or
withdrawal providing that one treatment arm or patient group
was randomised to steroid avoidance or withdrawal aDer more
than 14 days of treatment, and intention-to-treat rates of acute
rejection and pancreas and/or kidney allograD failure were
clearly established aDer steroid avoidance or use or withdrawal
or continuation.
Exclusion criteria
RCTs without a steroid avoidance or withdrawal group, i.e., RCTs
comparing immunosuppressive strategies that are not primarily
investigating steroid minimisation or avoidance.
Types of participants
Inclusion criteria• Pancreas transplant recipients, including first and
retransplantation in adult and paediatric recipients.• Isolated whole-organ pancreas, SPK and PAK transplant
recipients were included.
Exclusion criteria• Multiorgan (pancreas-liver, pancreas-intestine)
transplantations.• Islet transplantation.
Types of interventions• Steroid avoidance (or limited steroid use as induction during less
than 14 days) versus maintenance therapy• Late steroid withdrawal (aDer day 14 post-transplant) versus
steroid maintenance• Steroid avoidance (or limited steroid use as induction during less
than 14 days) versus late steroid withdrawal (aDer day 14 post-
transplant)
Types of outcome measures
Primary outcomes
1. Death
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2. GraD rejection (since transplantation, including rejection before
steroid cessation in steroid withdrawal patients)• Acute kidney rejection• Biopsy-proven acute kidney rejection• Acute pancreas rejection• Biopsy-proven acute pancreas rejection
3. GraD loss• Kidney graD loss including death with functioning graD• Kidney graD loss excluding death with functioning graD• Pancreas graD loss including death with function graD• Pancreas graD loss excluding death with function graD
Secondary outcomes
1. Laboratory findings• Serum creatinine (µmol/L)• Creatinine clearance (mL/min)• Worsening proteinuria (an increase by more than 50% of
baseline)• Serum cholesterol: total (mmol/L), LDL (mmol/L), HDL
(mmol/L)• Triglycerides (mmol/L)• HbA1c (%)
2. Clinical outcomes• Mean blood pressure (mm Hg)• Number of antihypertensive drugs (an increase in this
number)• Patients on lipid-lowering treatment• Bone density (% of variation)• Weight gain (in kg)
3. Adverse events• Number of cardiovascular events• Number of infections• Number of cataracts• Malignant neoplasia
The timing of the outcome assessments was that reported in the
studies.
Search methods for identification of studies
Electronic searches
We searched the Cochrane Renal Group's Specialised Register to
18 June 2014 through contact with the Trials' Search Co-ordinator
using search terms relevant to this review. The Cochrane Renal
Group’s Specialised Register contains studies identified from the
following sources.
1. Quarterly searches of the Cochrane Central Register of
Controlled Trials CENTRAL
2. Weekly searches of MEDLINE OVID SP
3. Handsearching of renal-related journals and the proceedings of
major renal conferences
4. Searching of the current year of EMBASE OVID SP
5. Weekly current awareness alerts for selected renal journals
6. Searches of the International Clinical Trials Register (ICTRP)
Search Portal and ClinicalTrials.gov.
Studies contained in the Specialised Register are identified through
search strategies for CENTRAL, MEDLINE, and EMBASE based on the
scope of the Cochrane Renal Group. Details of these strategies as
well as a list of handsearched journals, conference proceedings and
current awareness alerts are available in the Specialised Register
section of information about the Cochrane Renal Group.
See Appendix 1 for search terms used in strategies for this review.
Searching other resources
1. Reference lists of nephrology textbooks, clinical practice
guidelines, the list of references in recent important
publications and abstracts from international transplantation
society scientific meetings published and not published in
Transplantation journals, review articles and relevant studies.
2. Mails seeking information about unpublished or incomplete
studies to investigators known to be involved in previous
studies.
Data collection and analysis
Selection of studies
The review was undertaken by six authors. The search strategy
described was used to obtain titles and abstracts of studies relevant
to the review. The titles and abstracts were screened independently
by two authors who discarded studies that were not applicable:
however studies and reviews that potentially included relevant
data or information were retained initially. The same authors
assessed retrieved abstracts and, if necessary, the full text of these
studies to determine which studies satisfied the inclusion criteria.
Data extraction and management
Data extraction was carried out by two authors independently
using standardised data extraction forms. Any further information
required from the original author was requested by email and then
written correspondence and any relevant information obtained
in this manner was included in the review. Disagreements were
resolved in consultation with another author. Data was entered into
RevMan by one author.
Assessment of risk of bias in included studies
The following items were independently assessed by two authors
using the risk of bias assessment tool (Higgins 2011) (see Appendix
2). Discrepancies were resolved by discussion with a third author.
• Was there adequate sequence generation (selection bias)?• Was allocation adequately concealed (selection bias)?• Was knowledge of the allocated interventions adequately
prevented during the study (detection bias)?* Participants and personnel* Outcome assessors• Were incomplete outcome data adequately addressed (attrition
bias)?• Are reports of the study free of suggestion of selective outcome
reporting (reporting bias)?• Was the study apparently free of other problems that could put
it at a risk of bias?
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Measures of treatment e<ect
For dichotomous outcomes (acute rejection, graD failure, mortality)
results were expressed as risk ratios (RR) with 95% confidence
intervals (CI). When studies show no events, the RR is not estimable
and hence we used risk diLerence (RD) for these analyses to
check whether the overall conclusions were robust, as the RD
could be calculated using all studies. Where continuous scales
of measurement were used to assess the eLects of treatment
(blood pressure, serum cholesterol, kidney function measured by
serum creatinine, creatinine clearance, bone density) the mean
diLerence (MD) was used, or the standardised mean diLerence
(SMD) if diLerent scales were used.
Results of unfavourable dichotomous outcomes are expressed so
that the leD part in any graph indicates that steroid sparing strategy
is better than control. The same convention applies for MD and
SMD.
Dealing with missing data
Any further information required from the original author was
requested by written correspondence (e.g. emailing or writing to
corresponding author/s) and any relevant information obtained
in this manner was included in the review. Evaluation of
important numerical data such as screened, randomised patients
as well as intention-to-treat (ITT), as-treated and per-protocol (PP)
population was carefully performed. Attrition rates, for example
drop-outs, losses to follow-up and withdrawals were investigated.
Issues of missing data and imputation methods (for example,
last-observation-carried-forward (LOCF)) was critically appraised
(Higgins 2011).
Assessment of heterogeneity
Heterogeneity was analysed using a Chi2 test on N-1 degrees of
freedom, with an alpha of 0.05 used for statistical significance and
with the I2 test (Higgins 2003). I2 values of 25%, 50% and 75%
correspond to low, medium and high levels of heterogeneity. The I2
statistic calculates the proportion of total variation in the estimates
of treatment eLect due to heterogeneity beyond chance (Higgins
2003).
Assessment of reporting biases
We planned to use funnel plots to assess for the potential existence
of small study bias (Higgins 2011).
Data synthesis
Data was pooled using the random-eLects model but the fixed-
eLect model has also been analysed to ensure robustness of the
model chosen and susceptibility to outliers.
Were suLicient studies identified, we intended to undertake meta-
regression to check whether the two steroid sparing strategies
(withdrawal versus avoidance) had a significantly diLerent eLect
on any of the three considered most relevant outcomes (e.g.
kidney graD loss including death with function, pancreas graD loss
including death with function, acute kidney rejection).
Subgroup analysis and investigation of heterogeneity
Studies were grouped and analysed according to how steroids
were used within the immunosuppressive algorithm (see Types of
interventions).
1. Steroid avoidance (or limited steroid use as induction during less
than 14 days) versus maintenance therapy
2. Late steroid withdrawal (aDer day 14 post-transplant) versus
steroid maintenance
3. Steroid avoidance versus late steroid withdrawal
Were suLicient studies identified, we intended to undertake sub-
analyses within each comparison, stratifying results by calcineurin
inhibitor (CsA or TAC) and by anti-metabolite (MMF, myfortic or
mTOR inhibitor) treatment.
We intended to undertake subgroup analysis to explore possible
sources of heterogeneity (e.g. participants, interventions and study
quality). Heterogeneity among participants could be related to
age and renal pathology. Heterogeneity in treatments could be
related to prior agent(s) used and the agent, dose and duration
of therapy. Adverse eLects were tabulated and assessed with
descriptive techniques, since they would likely be diLerent for
the various agents used. Where possible, we calculated the risk
diLerence with 95% CI for each adverse eLect, either compared to
no treatment or to another agent.
Sensitivity analysis
We performed sensitivity analyses in order to explore the influence
of the following factors on eLect size: repeating the analysis
excluding unpublished studies; repeating the analysis taking
account of risk of bias, as specified above; repeating the analysis
excluding any very long or large studies to establish how much
they dominate the results; repeating the analysis excluding
studies using the following filters: diagnostic criteria, language of
publication, source of funding (industry versus other) or country.
R E S U L T S
Description of studies
Results of the search
The literature search consisted of a combined search of the
Cochrane Renal Group’s Specialised Register, MEDLINE, EMBASE,
and CENTRAL (to 18 June 2014) and also handsearched reference
lists of nephrology textbooks and recent publications, and
abstracts from international transplantation society scientific
meetings, reference lists of relevant studies, and sent emails
and letters seeking information about unpublished or incomplete
studies to investigators known to be involved in previous studies.
We identified 455 reports. Of these, 402 were excluded because
they evaluated wrong interventions (non-steroid avoidance/
withdrawal), were animal studies, included only kidney or
islet or liver transplantation or were duplicate reports. Full-
text assessment of 53 potentially eligible reports (22 studies)
identified three studies (5 reports) which met our inclusion
criteria (Cantarovich 2005; Gruessner 2001; Kandaswamy 2003).
Nineteen studies (48 reports) excluded were not randomised (15),
or investigated the wrong intervention (4). We did not find ongoing
studies potentially relevant to this review.
The combined search results are presented in Figure 1.
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Figure 1.   Flow chart showing source and identification of studies for inclusion
 
Included studies
See: Characteristics of included studies.
Five reports of three RCTs were included (Cantarovich 2005;
Gruessner 2001; Kandaswamy 2003). All were parallel studies; one
was performed in France and the other two in the USA. The
characteristics of participants were not described in Gruessner 2001
or Kandaswamy 2003. Cantarovich 2005 reported the median age
(IQR) was similar in the two intervention groups: steroid withdrawal
42 years (32-60), steroid avoidance 40 years (23-60); there were
more men than women (M/F): steroid withdrawal 16/9, steroid
avoidance 17/8 and they specified other relevant information such
as duration of diabetes (median, range): steroid withdrawal (25
years, 9 to 37), steroid avoidance (24 years, 12 to 35); number
of patients on chronic dialysis: steroid withdrawal (15, 60%),
steroid avoidance (16, 64%); and body weight (median, range):
steroid withdrawal (63 kg, 40 to 93), steroid avoidance (62 kg,
46 to 94). Cantarovich 2005 and Kandaswamy 2003 compared
steroid avoidance or early steroid withdrawal versus late steroid
withdrawal and Gruessner 2001 compared late steroid withdrawal
versus steroid maintenance. All of the included studies were
focused in SPK transplantation, and Gruessner 2001 also included
PAK; none involved PTA. Three diLerent immunosuppressive
strategies were used: with rabbit antithymocyte globulin (ATG) with
or without daclizumab for induction; and CsA or TAC with sirolimus
or MMF. The three studies presented only short-term results (six to
12 months). There were too few studies to subject the data to a
funnel plot.
One study contact author responded to queries about uncertainties
on study methods and randomisation (Cantarovich 2005) and three
study contact authors responded to queries about missing data
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stating they did not have the missing information (Cantarovich
2005; Gruessner 2001; Kandaswamy 2003).
All identified studies were published in English language; one study
was only reported as two conference abstracts (Kandaswamy 2003)
Excluded studies
See: Characteristics of excluded studies.
Nineteen studies (48 reports) were excluded, 14 studies of these
have been grouped together and investigated separately (see
below). The main reasons for exclusion were that studies were
not randomised (Aoun 2007; Fridell 2006; Hill 2009; Jepkorir
2012; Jordan 2000; Kahl 2001; Knight 2005; Lawrecki 2012; Luzi
2003; Malheiro 2009; Rajab 2007; Reichman 2011; Srinivas 2011;
Tanchanco 2008; Vessal 2007) or because the intervention was
not aimed at steroid withdrawal or avoidance (EURO-SPK 2002;
Kandaswamy 2002; Lefrancois 1987; Saudek 2004).
Risk of bias in included studies
Details of the risk of bias are given in the Risk of bias in included
studies table.
All the studies had an overall moderate risk of bias. All were judged
to be at high risk of performance and detection bias das they were
open-label studies. Gruessner 2001 was characterised as unclear
risk of bias in all of the domains: there was little information
reported about the randomisation method and no report if the
patients that dropped out the study were included in the main
analysis (unclear attrition bias) and also not all the data for all
stated outcomes was reported. See Figure 2 and Figure 3 for the
summary results for risk of bias.
 
Figure 2.   Risk of bias graph
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Figure 3.   Risk of bias summary
 
Using funnel plots to detect publication bias was not feasible
because of the small number of studies included in this review.
Allocation
Sequence generation
All three studies stated they were randomised however none
described how the randomisation was performed
Allocation concealment
Only Cantarovich 2005 reported adequate methods of allocation
concealment, the other two studies gave no clear indication of the
allocation method used.
Blinding
All the included studies were open-label and were judged to be at
high risk of bias.
Incomplete outcome data
Cantarovich 2005 specified that an intention-to-treat analysis was
performed, although they stated 11 patients in the two groups
needed treatment with steroids (due to the need of anti-rejection
therapy and for the interruption of the MMF), and three patients
remained on steroids chronically and it is unclear if they were
subsequently analysed. It was unclear if all the patients completed
follow-up in either Gruessner 2001 or Kandaswamy 2003.
Selective reporting
Data for all stated outcomes were reported, although important
information was missing information such as number of patients in
each group at each time point.
Other potential sources of bias
There was insuLicient information to assess whether any other
important risk of bias exists in any of the included studies. There
was no reported sponsorship for any of the included studies.
E<ects of interventions
Steroid avoidance or early withdrawal versus late steroid
withdrawal
Two studies compared steroid avoidance or early withdrawal (or
limited steroid use as induction during less than 14 days) versus
late steroid withdrawal (Kandaswamy 2003; Cantarovich 2005).
Duration of treatment ranged in the steroid withdrawal was from
three to six months and in the steroid avoidance group; one study
did not give any steroid at all (Cantarovich 2005), and in the other
Steroid avoidance or withdrawal for pancreas and pancreas with kidney transplant recipients (Review)
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induction therapy was given for four days (Kandaswamy 2003).
Follow-up was described only in one of the two studies and was
100%. As there were only two studies identified, we were not able
to perform subgroup analyses based on co-interventions and nor
could not explore heterogeneity.
All of the studies present only short-term results (from six to
maximum 12 months). Only 12 of the 24 possible outcomes were
reported and not all of them were reported in the two studies (Table
1). Due to there were few events and participants, we found wide
confidence intervals which included none eLect.
There was no significant diLerence in death at one year between
steroid avoidance or early withdrawal and late steroid withdrawal
(Analysis 1.1 (2 studies, 89 patients): RR 1.64, 95% CI 0.21 to 12.75).
No significant diLerence was reported by Cantarovich 2005 for
acute kidney rejection (all acute rejection Analysis 1.2.1 (49
patients): RR 2.08, 95% CI 0.20 to 21.50; biopsy-proven rejection
(Analysis 1.2.2 (49 patients): RR 1.04, 95% CI 0.07 to 15.73).
Cantarovich 2005 reported no acute pancreas rejection episodes
(all or biopsy-proven) (Analysis 1.3 (1 study, 49 patients).
Neither in the kidney loss outcome including (Analysis 1.4 (2
studies, 89 patients): RR 0.35, 95% CI 0.04 to 3.09) and excluding
death (Analysis 1.4 (2 studies, 89 patients): RR 0.75, 95% CI 0.18
to 3.05), nor in pancreas loss outcome censored (Analysis 1.5 (2
studies, 89 patients): RR 1.05, 95% CI 0.36 to 3.04) and not censored
for death (Analysis 1.5 (2 studies, 89 patients): RR 1.23, 95% CI 0.40
to 3.75).
Laboratory findings at six months showed no significant diLerences
between the steroid avoidance and late referral groups (Analysis
1.6 (2 studies, 89 patients): serum creatinine: MD 13.96 µmol/L 95%
CI -18.36 to 46.28; total serum cholesterol: MD 0.06 mmol/L 95%
CI -0.15 to 0.26; LDL cholesterol: MD 0.02 mmol/L 95% CI -0.20 to
0.23; HDL serum cholesterol: MD 0.09 mmol/L 95% CI -0.12 to 0.29;
triglycerides: MD -0.41 mmol/L 95% CI -1.10 to 0.28; and HbA1c: MD
0.08%, 95% CI -0.99 to 1.15).
Of the possible adverse eLects only infection was reported by
Cantarovich 2005. There were significantly more UTIs reported in
the late withdrawal group compared to the steroid avoidance group
(Analysis 1.7 (1 study, 25 patients): RR 0.41, 95% CI 0.26 to 0.66).
Late steroid withdrawal versus steroid maintenance
Gruessner 2001 compared late steroid withdrawal (steroid use
for more than 14 days) versus steroid maintenance. The steroid
withdrawal was completed within four to eight weeks. Duration
of follow-up was from eight to 50 months. Most outcomes were
reported at six months; no events were reported for death, acute
kidney rejection, kidney or pancreas lost (Analysis 2.1 (1 study, 48
participants). No kidney rejections were observed at six months in
either group, which is markedly diLerent from the usual clinical
experience. There was one episode of acute pancreas rejection in
each group ((Analysis 2.1.5 (1 study, 48 participants): RR 0.88, 95%
CI 0.06 to 13.35).
Meta-regression
There were insuLicient studies to pool estimates for subgroup
analyses for any of the outcomes.
Other outcomes
The following outcomes were not reported in any of the
included studies: worsening proteinuria; patients on lipid-lowering
treatment; number of cardiovascular events; number of cataracts;
bone density; weight gain; malignant neoplasia.
D I S C U S S I O N
This review provides little information to guide decisions on
steroid-sparing strategies in adult pancreas or pancreas with kidney
transplantation. More RCTs are necessary to provide any evidence
to support these immunosuppression regimens, but it is important
that they focus on the two most significant outcomes for these
transplant recipients: risk of graD loss and risk of rejection. A
greater number of RCTs are necessary to provide enough evidence
to show some eLect in mortality. Consequently, using long-term
observational data would be more pragmatic and should be
considered.
Summary of main results
We have assessed three randomised studies involving 144
participants in this systematic review of steroid-sparing strategies
in pancreas or pancreas with kidney transplantation.
As discussed in a meta-analysis of steroid-sparing strategies in
kidney transplantation published in 2009 (Pascual 2009), two
parameters are relevant when assessing these possible strategies:
the time when steroids are stopped and the duration of follow-up to
observe graD evolution without steroid treatment during adequate
periods of time.   In studies published on this topic, two main
steroid-sparing strategies are considered: steroid avoidance or very
early withdrawal and late steroid withdrawal. We defined steroid
avoidance or rapid steroid withdrawal as the limited use of steroids
as induction for less than 14 days and late steroid withdrawal as the
stopping of steroids aDer more than two weeks of treatment.
All of the included RCTs were focused in SPK transplantation,
one also included PAK and none involved PTA. The late steroid
withdrawal was undertaken in a range from three to six months and
in the two studies with steroid avoidance the therapy duration was
less than four days. Only one of the studies compared a steroid-
sparing strategy to a steroid maintenance therapy. Follow-up was
described only in one of the three studies and was 100%. Three
diLerent immunosuppressive strategies were used: rabbit ATG with
or without daclizumab for induction and CsA or TAC with sirolimus
or MMF.
All of the studies under-reported relevant data, especially related
to clinical outcomes and possible secondary eLects of steroid
treatment. Although we letters and emails seeking information
about that information to the study authors, we did not obtain any
positive responses. All of the studies only addressed the issue of
short-term results. As there were few events and participants in
the three studies, we found wide CIs crossing the line of no eLect.
There was uncertain direction of eLect on death, acute kidney
and pancreas rejection, with no diLerence in biopsy-proven cases
reported by Cantarovich 2005; kidney or pancreas loss including
and excluding death. Only Cantarovich 2005 reported the number
of infections and found a significantly higher number of UTIs in the
late withdrawal group compared to the steroid avoidance group.
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Overall completeness and applicability of evidence
The main problem of this review is that the data was incomplete in
several areas despite our comprehensive search and direct contact
with all of the authors of published studies; data found was only
of short-term outcomes. This review identified five reports of three
randomised studies enrolling 144 participants. All were open-label;
there was no blinding of researchers, assistants or patients. Only
one study reported adequate method of allocation concealment
and this was the only one that specified that an intention-to-
treat analysis was undertaken. Data for all stated outcomes was
reported, but there was relevant missing information that was
not obtained aDer contacting the authors. Outcome data for
pancreas or kidney transplant recipients were restricted generally
to transplant lost or rejection, and information about transplant
function, clinical outcomes (mean blood pressure, number of
antihypertensive drugs, bone density, weigh gain) or adverse
eLects (cardiovascular events, infections, cataracts or neoplasia)
were scarce. Moreover, no PTA recipients were included in any
study, so further research is needed in this population.
Quality of the evidence
Due to the lack of studies on the topic, our conclusions must be
considered cautiously due to several potential limitations in the
available data. Also we need to consider specially the high risk of
bias of the observational studies.
We are aware that the width of the CIs could reflect a lack of
statistical power which is directly related to the sample size of the
included studies. Cantarovich 2005 designed their study in order
to find a statistically significant diLerence between incidences
of biopsy proven acute rejection. They found a lower incidence
than expected and it was equal for both arms (4%), so therefore,
seeking diLerences for the outcomes we managed could result
underpowered. In the case of Kandaswamy 2003 the primary
outcome is not clearly specified, and neither is the sample size
estimation nor the power of the study. The same applies to
Gruessner 2001. Taking this information into account, it is diLicult
to make an accurate diagnosis about the appropriateness of the
sample size estimation in order to reach a feasible power, basically
because of a lack of information.
Potential biases in the review process
The main limitation of this review is that were very few RCTs
on this topic, they only presented short-term results and none
included PTA. Due to the fact that the major part of the published
literature consists of observational studies, we reviewed the results
separately here. This has been done previously (Pascual 2009)
and it seems necessary to consider them specially in the kidney
transplantation literature due to the little number of RCTs available.
Agreements and disagreements with other studies or
reviews
No previous reviews have been published on this topic.
Thirteen cohort studies and one RCT (which randomised two
diLerent immunosuppressive strategies based on TAC or CsA)
have investigated steroid withdrawal versus steroid maintenance
(EURO-SPK 2002; Jordan 2000; Kahl 2001; Malheiro 2009; Reichman
2011; Vessal 2007), steroid avoidance versus steroid maintenance
(Fridell 2006; Hill 2009; Knight 2005; Lawrecki 2012; Luzi 2003;
Rajab 2007; Tanchanco 2008) and early withdrawal versus early
minimisation versus steroid maintenance (Jepkorir 2012). These
studies showed that steroid-sparing and withdrawal strategies
have benefits in lowering HbA1c and risk of infections (BK virus
and CMV disease) and improved blood pressure control without
increasing the risk of rejection. Although in most of the studies there
was not a statistically significant increase of graD rejection or graD
loss, in two of the 14 studies, they found an increase of incidence
of acute pancreas rejection (HR 2.8, 95% CI 0.89 to 8.81, P = 0.066 in
one study and 43.3% in the steroid withdrawal group versus 9.3%
in the steroid maintenance, P < 0.05 at three years in the other)
and one out of 14 found an increase of incidence of acute kidney
rejection (18.7% in the steroid withdrawal group versus 2.8% in
the steroid maintenance, P < 0.05 at three years). There were not
diLerences between groups with respect to death.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
There is currently insuLicient evidence to determine the safety
and eLicacy of steroid withdrawal or avoidance in patients
receiving a whole pancreas isolated, simultaneous with a kidney
or aDer a kidney transplant. Observational studies have been
conducted among these patients reporting good results in
improving some clinical outcomes, however eLects on graD
rejection were uncertain.
Implications for research
We have identified an area of significant uncertainty for this
group of transplant recipients. Due to limited resources available
for research and the large number of clinical questions without
adequate answers, it is important to focus on the most relevant
ones. Perhaps in this case it would be more useful to run a large,
long-term RCT to answer the question of whether steroid-free
transplantation is a safe or better strategy rather than conducting
a systematic review or only perform RCTs focused on the two
most significant outcomes for these transplant recipients: risk of
graD loss and risk of rejection. It is also important to emphasize
important aspects of the graD rejection to be considered such
as the type of rejection (humoral or cellular) or the use of a
validated measurement scales to grade the rejection (i.e. BanL
classification). Currently there is no large, long-term RCT underway,
therefore several RCTs are necessary to provide enough evidence
to show some eLect on mortality. At this point in time using long-
term observational data would be more pragmatic and should be
considered when investigating harms.
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Characteristics of included studies [ordered by study ID]
 
Methods • Study design: parallel RCT• Study duration: January 1999 to November 2002• Completeness of follow-up: 100%
Participants • Setting: single centre (Nantes University Hospital)• Country: France• Relevant health status: negative T-cell cross-match on past and pretransplant sera; SPK transplant
recipients• Number: steroid withdrawal (25); steroid avoidance (25)• Median age, IQR (years): steroid withdrawal (42, 32-60); steroid avoidance (40, 23-60)• Sex (M/F): steroid withdrawal (16/9); steroid avoidance (17/8)• Other relevant information* Duration of diabetes (median years, IQR): steroid withdrawal (25, 9–37); steroid avoidance (24, 12–
35)* Number on chronic dialysis: steroid withdrawal (15); steroid avoidance (16)* Median body weight, IQR (kg): steroid withdrawal (63, 40–93); steroid avoidance (62, 46–94)* Number with positive PRA > 50%: steroid withdrawal (8); steroid avoidance 3 (12%)* Range of anti-HLA immunization: steroid withdrawal (3-8%); steroid avoidance (6–30%)• Exclusion criteria: non-heart beating donors; patients with known sensitivity to thymoglobulin, CsA
or MMF; patients who were pregnant and patients with any of the human immunodeficiency viruses
Interventions Steroid withdrawal group (steroids in the first 3 months following transplantation)
• Pre-transplant dose: 500 mg methylprednisolone hemisuccinate• For 2 days: 1 mg/kg oral prednisone• Followed for 2 days: 0.5 mg/kg oral prednisone• Followed by a tapering regimen of reduction of 5 mg every 5 days, until maintenance dose of 10 mg/d• Discontinuation on post-operative day 90
Steroid avoidance group
• None, unless needed during treatment of rejection episode with the monoclonal antibody anti-CD3
Co-interventions
• ATG: for 10-day induction course, 75 mg first dose, subsequent doses adjusted according to E-rossette
test• MMF: 1 g/12 h• CsA: first 3 patients started on day 10, remaining 47 patients immediately after surgery 10 mg/kg di-
vided into 2 doses 12 h apart
Cantarovich 2005 
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Outcomes Reported outcomes (at 12 months)
• Acute kidney rejection• Biopsy-proven acute kidney rejection, BanL grade• Acute pancreas rejection• ATG course and cumulative dose• Switch to horse ALG or to tacrolimus• Fever (1st month)• Acute serum sickness• Duration of hospitalisation• Number of infections• Malignant neoplasia (including post-transplant lymphoproliferative disorder)• Adverse effects or serious adverse effects (number of patients, and total number of episodes)• Serum creatinine (µmol/L;, fasting glycaemia (mmol/L); fasting insulinaemia (µUI/L); HbA1c (%);
serum cholesterol (mmol/L, total, LDL, HDL), triglycerides (mmol/L)
Patient and graD survival (1-5 years)
• Kidney graD loss including death with functioning graD• Kidney graD loss excluding death with functioning graD• Pancreas graD loss including death with function graD• Pancreas graD loss excluding death with function graD
Notes • Non funding source• Required contact with study authors for additional information: last one: 16/10/2012
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Non details about sequence generation, but quote: “Closed envelopes includ-
ing the name of each arm (steroid withdrawal or steroid avoidance) were used
for randomisation, which was stratified by recipient age (more or less than 50
years) and by panel-reactive T-cell alloantibodies (more or less than 50%).”
Allocation concealment
(selection bias)
Low risk Quote: “Closed envelopes including the name of each arm (steroid withdrawal
or steroid avoidance) were used for randomisation." Comment: not specified if
were used without appropriate safeguards
Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk One patient who died on post-operative day 2 was excluded.
Intention to treat analysis. “From the 11 patients to whom steroids were given
(5 in the avoidance and 6 in the withdrawal groups, respectively) (anti-rejec-
tion therapy = 4 and MMF interruption = 7), only 3 remained on steroids chron-
ically." Comment: not described the group of those who remained on steroids
chronically
Selective reporting (re-
porting bias)
Low risk Data for all stated outcomes reported
Other bias Low risk No sponsorship
Cantarovich 2005  (Continued)
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Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: SPK: median 27 months (range 10 to 50), PAK: median 26 months (range 8 to 49)
Participants • Setting: NS• Country: USA (Minnesota)• Relevant health status: functioning graDs ≥ 6 and ≤ 36 months after SPK or PAK; full kidney func-
tion (dialysis free) and pancreas function (insulin free and normoglycaemic); no rejection episode ≤
6 months before enrolment• Number: SPK (29); PAK (26)* SPK: steroid withdrawal (16); standard immunosuppression (13)* PAK: steroid withdrawal (14); standard immunosuppression (12)• Age: NS• Sex (M/F): NS• Other relevant information: NS• Exclusion criteria: NS
Interventions Steroid withdrawal
• Steroid withdrawal completed within 4 to 8 weeks
Standard immunosuppression
• Low maintenance steroid dose: 0.075 mg/kg
Co-interventions
• Quadruple therapy for induction and triple therapy for maintenance immunosuppression (tacrolimus
at levels ≥ 8 ng/mL and mycophenolate mofetil (MMF) ≥ 0.75 g/12 h, low maintenance steroid dose
(0.075 mg/kg)
Outcomes Reported outcomes in PAK and in SPK category (at 6 months)
• Patient, kidney and pancreas graD survival• Rejection episodes• Steroid side effects: gastrointestinal (e.g. nausea, vomiting), ophthalmological (e.g. blurry vision), psy-
chological (e.g. anxiety), skin (e.g. acne), appearance (e.g. puffiness)• Weight• Serum creatinine levels; urinary amylase levels; cholesterol; triglycerides
Notes • No funding source• Required contact with study authors for additional information without clarification of the doubts:
last one: 16/10/2012
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “we performed a prospective, randomised, open-label study”
Comment: method not described
Allocation concealment
(selection bias)
Unclear risk Quote: “we performed a prospective, randomised, open-label study”
Comment: method not described
Gruessner 2001 
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Blinding (performance
bias and detection bias) 
All outcomes
High risk Open-label
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Quote: "A total of six recipients dropped out of the study (five SPK, one PAK): in
the control group, two recipients dropped out because of debilitating steroid
side effects; in the withdrawal group, three recipients dropped out because of
MMF doses below study criteria and one because of steroid use for treatment
of pericarditis".
Comment: Not specified if all these patients were included in main analysis
Selective reporting (re-
porting bias)
Unclear risk Not all the data for all stated outcomes reported
Other bias Unclear risk There is insufficient information to assess whether an important risk of bias ex-
ists
Gruessner 2001  (Continued)
 
 
Methods • Study design: parallel RCT• Study duration: NS• Duration of follow-up: NS
Participants • Setting: NS• Country: USA (Minnesota)• Relevant health status: SPK transplant recipients• Number: rapid steroid withdrawal (19), delayed steroid withdrawal (20)• Age: NS• Sex (M/F): NS• Other relevant information: NS• Exclusion criteria: NS
Interventions Rapid steroid withdrawal
• Steroids for 4 days only
Delayed steroid withdrawal
• Prednisone tapered to 5 mg at 3 months and 0 mg at 6 months
Co-interventions
• ATG (1.25 mg/kg x 1 if immediate kidney function, x 5-10 if delayed)• Daclizumab (1 mg/kg x 2) for induction and sirolimus and tacrolimus for maintenance
Outcomes Reported outcomes (at 6 months)
• Rejection episodes• Side effects: nausea, vomiting, diarrhoea, arthralgias, tremors and headaches• Serum Hb, white blood cells, creatinine, amylase, lipase, HbA1c, cholesterol, triglycerides, HDL, LDL,
tacrolimus level• Patient and graD survival (at 1 year)
Notes • SPK• Non funding source
Kandaswamy 2003 
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• Required contact with study authors for additional information without answer: last one: 16/10/2012
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: “A prospective, randomised trial". Comment: method not described
Allocation concealment
(selection bias)
Unclear risk Quote: “A prospective, randomised trial". Comment: method not described
Blinding (performance
bias and detection bias) 
All outcomes
High risk Not described as “blinded study”. Comparison of two active treatment groups
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk Not clear if all patients had completed follow up data
Selective reporting (re-
porting bias)
Low risk Data for all stated outcomes reported
Other bias Unclear risk There is insufficient information to assess whether an important risk of bias ex-
ists
Kandaswamy 2003  (Continued)
ATG - antithymocyte globulin; CsA - cyclosporin A; IQR - interquartile range; MMF - mycophenolate mofetil; NS - not stated; PAK - pancreas
aDer kidney transplant; PRA - panel reactive antibodies; SPK - simultaneous pancreas-kidney transplant
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Aoun 2007 Not RCT
EURO-SPK 2002 Not correct intervention (randomised to tacrolimus or cyclosporin). Included as an observational
study in the discussion section Table 2; Table 3
Fridell 2006 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Hill 2009 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Jepkorir 2012 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Jordan 2000 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Kahl 2001 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Kandaswamy 2002 Not correct intervention (RCT without a steroid avoidance or withdrawal group)
Knight 2005 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Lawrecki 2012 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Lefrancois 1987 Unsure randomisation. Not correct intervention (without a steroid avoidance or withdrawal group)
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Study Reason for exclusion
Luzi 2003 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Malheiro 2009 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Rajab 2007 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Reichman 2011 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Saudek 2004 Not correct intervention (RCT without a steroid avoidance or withdrawal group)
Srinivas 2011 Not RCT
Tanchanco 2008 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
Vessal 2007 Not RCT. Included as an observational study in the discussion section Table 2; Table 3
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Steroid avoidance versus late (aHer day 14 post-transplant) steroid withdrawal
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Death at 1 year 2 89 Risk Ratio (M-H, Random, 95% CI) 1.64 [0.21, 12.75]
2 Acute kidney rejection (1 year) 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.1 All acute rejection 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
2.2 Biopsy-proven rejection 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3 Acute pancreas rejection (1 year) 1 98 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.1 All acute rejection 1 49 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
3.2 Biopsy-proven rejection 1 49 Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
4 Kidney lost (1 year) 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 Censored for death 2 89 Risk Ratio (M-H, Random, 95% CI) 0.35 [0.04, 3.09]
4.2 Not censored for death 2 89 Risk Ratio (M-H, Random, 95% CI) 0.75 [0.18, 3.05]
5 Pancreas lost (1 year) 2   Risk Ratio (M-H, Random, 95% CI) Subtotals only
5.1 Censored for death 2 89 Risk Ratio (M-H, Random, 95% CI) 1.05 [0.36, 3.04]
5.2 Not censored for death 2 89 Risk Ratio (M-H, Random, 95% CI) 1.23 [0.40, 3.75]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
6 Laboratory findings at 6 months 2   Mean Difference (IV, Random,
95% CI)
Subtotals only
6.1 Serum creatinine [µmol/L] 2 89 Mean Difference (IV, Random,
95% CI)
13.96 [-18.36, 46.28]
6.2 Total serum cholesterol [mmol/L] 2 89 Mean Difference (IV, Random,
95% CI)
0.06 [-0.15, 0.26]
6.3 LDL serum cholesterol [mmol/L] 2 89 Mean Difference (IV, Random,
95% CI)
0.02 [-0.20, 0.23]
6.4 HDL serum cholesterol [mmol/L] 2 89 Mean Difference (IV, Random,
95% CI)
0.09 [-0.12, 0.29]
6.5 Triglycerides [mmol/L] 2 89 Mean Difference (IV, Random,
95% CI)
-0.41 [-1.10, 0.28]
6.6 HbA1c [%] 2 89 Mean Difference (IV, Random,
95% CI)
0.08 [-0.99, 1.15]
7 Infections 1   Risk Ratio (M-H, Random, 95% CI) Totals not selected
7.1 Total 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.2 CMV 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.3 Urinary infection 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
7.4 Broncho-pulmonary infection 1   Risk Ratio (M-H, Random, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 1.1.   Comparison 1 Steroid avoidance versus late (aHer day
14 post-transplant) steroid withdrawal, Outcome 1 Death at 1 year.
Study or subgroup Steroid
avoidance
Late steroid
withdrawal
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Cantarovich 2005 1/25 0/25 42.28% 3[0.13,70.3]
Kandaswamy 2003 1/19 1/20 57.72% 1.05[0.07,15.66]
   
Total (95% CI) 44 45 100% 1.64[0.21,12.75]
Total events: 2 (Steroid avoidance), 1 (Late steroid withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.25, df=1(P=0.62); I2=0%  
Test for overall effect: Z=0.47(P=0.64)  
Steroid avoidance 1000.01 100.1 1 Late steroid withdrawal
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Analysis 1.2.   Comparison 1 Steroid avoidance versus late (aHer day 14 post-
transplant) steroid withdrawal, Outcome 2 Acute kidney rejection (1 year).
Study or subgroup Steroid avoidance Late steroid withdrawal Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.2.1 All acute rejection  
Cantarovich 2005 2/24 1/25 2.08[0.2,21.5]
   
1.2.2 Biopsy-proven rejection  
Cantarovich 2005 1/24 1/25 1.04[0.07,15.73]
Steroid avoidance 1000.01 100.1 1 Late withdrawal
 
 
Analysis 1.3.   Comparison 1 Steroid avoidance versus late (aHer day 14 post-
transplant) steroid withdrawal, Outcome 3 Acute pancreas rejection (1 year).
Study or subgroup Steroid
avoidance
Late steroid
withdrawal
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.3.1 All acute rejection  
Cantarovich 2005 0/24 0/25   Not estimable
Subtotal (95% CI) 24 25 Not estimable
Total events: 0 (Steroid avoidance), 0 (Late steroid withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
1.3.2 Biopsy-proven rejection  
Cantarovich 2005 0/24 0/25   Not estimable
Subtotal (95% CI) 24 25 Not estimable
Total events: 0 (Steroid avoidance), 0 (Late steroid withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
Total (95% CI) 48 50 Not estimable
Total events: 0 (Steroid avoidance), 0 (Late steroid withdrawal)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Steroid avoidance 10000.001 100.1 1 Late steroid withdrawal
 
 
Analysis 1.4.   Comparison 1 Steroid avoidance versus late (aHer day 14
post-transplant) steroid withdrawal, Outcome 4 Kidney lost (1 year).
Study or subgroup Steroid
avoidance
Late steroid
withdrawal
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 Censored for death  
Cantarovich 2005 0/25 0/25   Not estimable
Kandaswamy 2003 1/19 3/20 100% 0.35[0.04,3.09]
Subtotal (95% CI) 44 45 100% 0.35[0.04,3.09]
Total events: 1 (Steroid avoidance), 3 (Late steroid withdrawal)  
Steroid avoidance 10000.001 100.1 1 Late steroid withdrawal
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Study or subgroup Steroid
avoidance
Late steroid
withdrawal
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Z=0.94(P=0.35)  
   
1.4.2 Not censored for death  
Cantarovich 2005 1/25 0/25 20% 3[0.13,70.3]
Kandaswamy 2003 2/19 4/20 80% 0.53[0.11,2.55]
Subtotal (95% CI) 44 45 100% 0.75[0.18,3.05]
Total events: 3 (Steroid avoidance), 4 (Late steroid withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.95, df=1(P=0.33); I2=0%  
Test for overall effect: Z=0.41(P=0.68)  
Test for subgroup differences: Chi2=0.32, df=1 (P=0.57), I2=0%  
Steroid avoidance 10000.001 100.1 1 Late steroid withdrawal
 
 
Analysis 1.5.   Comparison 1 Steroid avoidance versus late (aHer day 14
post-transplant) steroid withdrawal, Outcome 5 Pancreas lost (1 year).
Study or subgroup Steroid
avoidance
Late steroid
withdrawal
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.5.1 Censored for death  
Cantarovich 2005 2/25 3/25 38.95% 0.67[0.12,3.65]
Kandaswamy 2003 4/19 3/20 61.05% 1.4[0.36,5.46]
Subtotal (95% CI) 44 45 100% 1.05[0.36,3.04]
Total events: 6 (Steroid avoidance), 6 (Late steroid withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.45, df=1(P=0.5); I2=0%  
Test for overall effect: Z=0.09(P=0.93)  
   
1.5.2 Not censored for death  
Cantarovich 2005 3/25 3/25 55.47% 1[0.22,4.49]
Kandaswamy 2003 3/19 2/20 44.53% 1.58[0.3,8.43]
Subtotal (95% CI) 44 45 100% 1.23[0.4,3.75]
Total events: 6 (Steroid avoidance), 5 (Late steroid withdrawal)  
Heterogeneity: Tau2=0; Chi2=0.16, df=1(P=0.69); I2=0%  
Test for overall effect: Z=0.36(P=0.72)  
Test for subgroup differences: Chi2=0.04, df=1 (P=0.84), I2=0%  
Steroid avoidance 100.1 50.2 20.5 1 Late steroid withdrawal
 
 
Analysis 1.6.   Comparison 1 Steroid avoidance versus late (aHer day 14 post-
transplant) steroid withdrawal, Outcome 6 Laboratory findings at 6 months.
Study or subgroup Steroid avoidance Late steroid
withdrawal
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
1.6.1 Serum creatinine [µmol/L]  
Cantarovich 2005 25 119 (30) 25 112 (30) 84.88% 7[-9.63,23.63]
Kandaswamy 2003 19 168 (168) 20 114.9 (36.4) 15.12% 53.04[-24.15,130.23]
Steroid avoidance 200100-200 -100 0 Late steroid withdrawal
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Study or subgroup Steroid avoidance Late steroid
withdrawal
Mean Difference Weight Mean Difference
  N Mean(SD) N Mean(SD) Random, 95% CI   Random, 95% CI
Subtotal *** 44   45   100% 13.96[-18.36,46.28]
Heterogeneity: Tau2=248.41; Chi2=1.31, df=1(P=0.25); I2=23.44%  
Test for overall effect: Z=0.85(P=0.4)  
   
1.6.2 Total serum cholesterol [mmol/L]  
Cantarovich 2005 25 2 (0.5) 25 2 (0.3) 81.53% 0.07[-0.16,0.3]
Kandaswamy 2003 19 4.9 (0.8) 20 4.9 (0.8) 18.47% 0[-0.48,0.48]
Subtotal *** 44   45   100% 0.06[-0.15,0.26]
Heterogeneity: Tau2=0; Chi2=0.07, df=1(P=0.8); I2=0%  
Test for overall effect: Z=0.54(P=0.59)  
   
1.6.3 LDL serum cholesterol [mmol/L]  
Cantarovich 2005 25 1.1 (0.5) 25 1.1 (0.3) 87.77% 0[-0.23,0.23]
Kandaswamy 2003 19 2.8 (1.2) 20 2.7 (0.6) 12.23% 0.13[-0.48,0.74]
Subtotal *** 44   45   100% 0.02[-0.2,0.23]
Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%  
Test for overall effect: Z=0.15(P=0.88)  
   
1.6.4 HDL serum cholesterol [mmol/L]  
Cantarovich 2005 25 0.5 (0.1) 25 0.5 (0.1) 58.88% 0[-0.06,0.06]
Kandaswamy 2003 19 1.4 (0.3) 20 1.1 (0.3) 41.12% 0.21[0.03,0.39]
Subtotal *** 44   45   100% 0.09[-0.12,0.29]
Heterogeneity: Tau2=0.02; Chi2=4.68, df=1(P=0.03); I2=78.61%  
Test for overall effect: Z=0.84(P=0.4)  
   
1.6.5 Triglycerides [mmol/L]  
Cantarovich 2005 25 1.1 (0.3) 25 1.2 (0.5) 53.57% -0.08[-0.31,0.15]
Kandaswamy 2003 19 1.4 (0.3) 20 2.2 (0.9) 46.43% -0.79[-1.23,-0.35]
Subtotal *** 44   45   100% -0.41[-1.1,0.28]
Heterogeneity: Tau2=0.22; Chi2=7.98, df=1(P=0); I2=87.47%  
Test for overall effect: Z=1.16(P=0.25)  
   
1.6.6 HbA1c [%]  
Cantarovich 2005 25 5 (0.9) 25 5.4 (0.7) 56.03% -0.4[-0.85,0.05]
Kandaswamy 2003 19 6.5 (1.9) 20 5.8 (0.4) 43.97% 0.7[-0.17,1.57]
Subtotal *** 44   45   100% 0.08[-0.99,1.15]
Heterogeneity: Tau2=0.48; Chi2=4.84, df=1(P=0.03); I2=79.34%  
Test for overall effect: Z=0.15(P=0.88)  
Test for subgroup differences: Chi2=2.61, df=1 (P=0.76), I2=0%  
Steroid avoidance 200100-200 -100 0 Late steroid withdrawal
 
 
Analysis 1.7.   Comparison 1 Steroid avoidance versus late (aHer
day 14 post-transplant) steroid withdrawal, Outcome 7 Infections.
Study or subgroup Steroid avoidance Late steroid withdrawal Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
1.7.1 Total  
Cantarovich 2005 17/25 25/25 0.69[0.52,0.9]
Steroid avoidance 1000.01 100.1 1 Late steroid withdrawal
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Study or subgroup Steroid avoidance Late steroid withdrawal Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
   
1.7.2 CMV  
Cantarovich 2005 1/25 1/25 1[0.07,15.12]
   
1.7.3 Urinary infection  
Cantarovich 2005 10/25 25/25 0.41[0.26,0.66]
   
1.7.4 Broncho-pulmonary infection  
Cantarovich 2005 6/25 1/25 6[0.78,46.29]
Steroid avoidance 1000.01 100.1 1 Late steroid withdrawal
 
 
Comparison 2.   Late steroid withdrawal (more than 14 days) versus steroid maintenance
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Outcomes at 6 months 1   Risk Ratio (M-H, Random, 95%
CI)
Totals not selected
1.1 Death 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.2 Acute kidney rejection 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.3 Kidney lost: censored for death 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.4 Kidney lost: not censored for death 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.5 Acute pancreas rejection 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.6 Pancreas lost: censored for death 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
1.7 Pancreas lost: not censored for death 1   Risk Ratio (M-H, Random, 95%
CI)
0.0 [0.0, 0.0]
 
 
Analysis 2.1.   Comparison 2 Late steroid withdrawal (more than 14
days) versus steroid maintenance, Outcome 1 Outcomes at 6 months.
Study or subgroup Late steroid withdrawal Steroid maintenance Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
2.1.1 Death  
Gruessner 2001 0/26 0/23 Not estimable
Late steroid withdrawal 10000.001 100.1 1 Steroid maintenance
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Study or subgroup Late steroid withdrawal Steroid maintenance Risk Ratio Risk Ratio
  n/N n/N M-H, Random, 95% CI M-H, Random, 95% CI
   
2.1.2 Acute kidney rejection  
Gruessner 2001 0/26 0/23 Not estimable
   
2.1.3 Kidney lost: censored for death  
Gruessner 2001 0/26 0/23 Not estimable
   
2.1.4 Kidney lost: not censored for death  
Gruessner 2001 0/26 0/23 Not estimable
   
2.1.5 Acute pancreas rejection  
Gruessner 2001 1/26 1/23 0.88[0.06,13.35]
   
2.1.6 Pancreas lost: censored for death  
Gruessner 2001 0/26 0/23 Not estimable
   
2.1.7 Pancreas lost: not censored for death  
Gruessner 2001 0/26 0/23 Not estimable
Late steroid withdrawal 10000.001 100.1 1 Steroid maintenance
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Studies; time points of outcomes reported
Cantarovich
2005
Gruessner
2001
Kan-
daswamy
2003
Outcomes
3m6m1y 2y3y4y5y3m6m1y2y3y4y5y3m6m1y 2y3y4y5y
Death     •           •               • • • • •
Acute rejection                 •                        Kidney
Biopsy-proven                                          
Acute rejection                 •                        
GraD
Rejection
Pancreas
Biopsy-proven                                          
Censored for death     •                           •        Kidney
Not censored for death     •                           •        
Censored for death     •                           •        
GraD
Loss
Pancreas
Not censored for death     •                           •        
Serum creatinine • • •           •             •          
Creatinine clearance                                          
Worsening proteinuria (increase > 50%)                                           
Total • • •           •             •          
LDL • • •                         •          
Serum
cholesterol
HDL • • •                         •          
Triglycerides • • •           •             •          
Laboratory
findings
HbA1c (%) • • •                         •          
Table 1.   Outcomes reported in the included studies  (Continued)
Cochrane
Library
Trusted evidence.
Inform
ed decisions.
Better health.
  
Cochrane Database of System
atic Review
s
Steroid avoidance or w
ithdraw
al for pancreas and pancreas w
ith kidney transplant recipients (Review
)
Copyright ©
 2014 The Cochrane Collaboration. Published by John W
iley & Sons, Ltd.
29
Mean blood pressure (mm Hg)                                          
Antihypertensive drugs                                          
Bone density (% of variation)                                          
Clinical
outcomes
Weight gain (Kg)                                          
Cardiovascular events                                          
Infections     •                                    
Cataracts                                          
Adverse
effects
Malignant neoplasia     •                                    
Table 1.   Outcomes reported in the included studies  (Continued)
mo: month, y: year. When cells are leD empty complete data were unavailable
 
 
Compar-
isons
Study ID Trans-
plant type
(n)
Design Duration and
follow-up
Study total,
steroids
stopped
Time
to stop-
ping
steroids
Co-interventions Additional in-
formation
Jordan
2000
PTA (13)
SPK (177)
PAK (20)
Observational retro-
spective cohort study
Jul 1994 to Jul 1999
Mean follow-up: 3.3 ±
1.5 y
Total: 210
Excluded: 36
SW: 80
SM: 94
Mean:
15.9 ± 8
months
TAC + MMF or AZA +
prednisone
Outcome af-
ter successful
engraftment
after the first
3 months
Kahl 2001 SPK Observational retro-
spective cohort study
Jun 1996 to Jun 1998
Median follow-up: 2.9
(min 2.25, max 4.16) y
Total: 35
Excluded: 3 SW:
23
SM: 9
12 months ATG + TAC + MMF + pred-
nisone
 
Steroid
withdraw-
al versus
steroid
mainte-
nance
EURO-SPK
2002
SPK RCT 2 groups: TAC vs
CsA
May 1998 to Sept 2000 Total: 232
Excluded: 27
Mean TAC
group: 9.3
mo
ATG + TAC or CsA + MMF
+ prednisone
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SW: at 6 mo (31);
at 1 y (65); at 3 y
(91)
SM: at 6 mo (108);
at 1 y (62); at 3 y
(99)
Mean CsA
group: 7.8
mo
Vessal
2007
PTA (19)
SPK (18)
PAK (17)
Observational with ret-
rospective cohort con-
trol study
Jan 2001 to Dec 2003
Mean follow-up: SW
(12.04 ± 0.6 mo); SM
(11.2 ± 2.63 mo)
Total: 54
SW: 22 SM: 32
Postoper-
ative day
21
ATG + TAC + MMF
(changed to sirolimus in
2 patients or suspended
in 4) + prednisone
3 high im-
munologic
risk patients
(African-
Americans
with PRA >
40% or with
previous pan-
creas trans-
plants) in-
cluded in SW
group
Malheiro
2009
SPK Observational retro-
spective cohort study
May 2000 to Dec 2007
Mean follow-up: 38.51
± 25.87 mo
Total: 77
Patients with
more than 1 y fol-
low-up:
SW (42); SM (12)
Started at
6 months,
complete
suspen-
sion by the
end of 1st
year
ATG + TAC + MMF
(changed to Myf in 4 pa-
tients or sirolimus in 23)
+ prednisone
Excluded
from the SW
group: pre-
vious acute
rejection
episode, gas-
trointestinal
intolerance
to MMF, pre-
vious severe
infectious
episodes and
presence
of BK virus
nephritis
Reichman
2011
SPK (76)
PAK (12)
Observational retro-
spective cohort study
Mean follow-up: 38.51
± 25.87 mo
Total: 88
SW: 45
SM: 43
Mean 35 ±
20 months
  Inclusion cri-
teria: stable
graD func-
tion at 6
months with-
out episodes
of acute rejec-
tion
Table 2.   Characteristics of additional studies analysed  (Continued)
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Luzi 2003 SPK (31)
Kidney
alone (6)
Observational
prospective cohort
study
  Total: 31
SA: 19
SM: 12
  CsA + AZA + prednisone Study start-
ed with trans-
plant age be-
tween 3 to 5
years
Knight
2005
SPK Observational with ret-
rospective cohort con-
trol study
Mean follow-up 24
months
Total: 42
SA: 20
SM: 22
Postoper-
ative day 5
SA: ATG + sirolimus + CsA
(in SA group at 6 months
replaced it with Myf)
SM: sirolimus + CsA +
prednisone
Only low im-
munologic
risk patients
in SA group
(non African-
Americans
with PRA <
50%, receiv-
ing a primary
transplant).
Most common
adverse effect
was wound
complication
(without dif-
ferences be-
tween groups)
Fridell
2006
PAK Observational with ret-
rospective cohort con-
trol study
Jun 2003 to Jan 2006
Mean follow-up: SA (13
± 3.8 mo); SM (27.6 ±
3.6 mo)
Total: 29
SA: 19
SM: 10
Postoper-
ative day 5
ATG + TAC + sirolimus +
prednisone
Similar ac-
tuarial inci-
dence of in-
fections
Rajab
2007
PTA (184)
SPK (32)
PAK (5)
Observational retro-
spective cohort study
Aug 2003 to May 2006 Total: 221
SA: 97
SM: 124
Postoper-
ative day 5
SA: ATG + sirolimus + CsA
+ prednisone
SM: basiliximab + CsA +
MMF + prednisone
 
Tanchan-
co 2008
PTA (17)
SPK (22)
PAK (48)
Observational with ret-
rospective cohort con-
trol study
Jan 2000 to Nov 2006 Total: 87
SA: 25
SM: 62
Postoper-
ative day 6
ATG + TAC + MMF + pred-
nisone
Shorter peri-
od follow-up
in the SA
group
Steroid
avoidance
versus
steroid
mainte-
nance
Hill 2009 PAK Observational retro-
spective cohort study
Dec 1999 to Dec 2007 Total: 104
SA: 58
  ATG + TAC or CsA + pred-
nisone
 
Table 2.   Characteristics of additional studies analysed  (Continued)
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Mean follow-up: SA (80
mo); SM (53.9 mo)
SM: 46
Lawrecki
2012
SPK Observational retro-
spective cohort study
Jan 1997 to Oct 2010 Total: 79
SA: 46
SM: 33
Postoper-
ative day 5
ATG + TAC + Myf + pred-
nisone
 
Early
steroid
withdraw-
al versus
early
steroid
minimisa-
tion ver-
sus
steroid
mainte-
nance
Jepkorir
2012
SPK Observational retro-
spective cohort study
Mean follow-up: ESW
(75.3 mo); ESM (26.7
mo); SM (111.8 mo)
Total: 110
ESW: 42
ESM: 45
SM: 23
  ATG + TAC + Myf + pred-
nisone
ESW and
ESM received
greater ATG
cumulative
dosing
Table 2.   Characteristics of additional studies analysed  (Continued)
ATG - anti-thymocyte globulin; AZA - azathioprine; CsA - cyclosporin; ESW - early steroid withdrawal; ESM - early steroid minimisation; Myf - myfortic; MMF - mycophenolate mofetil
- PAK: pancreas aDer kidney; PRA - panel reactive antibodies; PTA - pancreas transplant alone; SPK - simultaneous pancreas and kidney; SA - steroid avoidance; SM - steroid
maintenance; SW - steroid withdrawal; TAC - tacrolimus; y - year/s
 
 
Compari-
son
Study ID Kidney loss Pancreas loss Kidney acute
rejection
Pancreas acute rejec-
tion
Death (n or
%)
Benefits of
stopping
Harms of
stopping
Steroid
withdraw-
al versus
steroid
mainte-
nance
Jordan
2000
At > 3 mo:
3 vs 7 (P NS)
At 1 y: 0% vs 1%
(P 0.001)
At > 3 mo:
2 vs 12 (P NS)
At 1 y: 6% vs
12% (P 0.001)
(Biopsy con-
firmed)
2 vs 3 (P NS)
SW: 0.88 ± 0.9
episodes/pa-
tient
SM: 1.68 ± 4
episodes/pa-
tient
(Biopsy confirmed)
1 vs 8 (P NS)
At 1 y: 0% vs
2% (P 0.002)
Less HbA1c and bet-
ter SCr level
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Kahl 2001 At 1 y: total 3% At 1 y: total 89% At 35 mo: 17
(43%) vs 3
(33%) (P NS)
Survival at 1 y:
0 vs 0
At 35 mo: 0 Higher MMF dose.
More late rejection
episodes
 
At 6 mo: 24 (26.4%) vs 68 (59.6%) (P NS)
At 1 y: 18 (27.7%) vs 23 (37%) (P NS)
At 3 y: 9 (9.8%) vs 63 (69.2%) (P NS)
EURO-SPK
2002
At 6 mo: 0 vs 7
(P NS)
At 3 y: 3 (3.3%)
vs 4 (3.8%) (P
NS)
At 6 mo: 0 vs 27 (P NS)
At 3 y: 3 (3.3%) vs 9
(10.71%) (P NS)
At 1 year:
total 88 (biopsy
proven: 63)
At 1 year:
total 9 (biopsy proven:
4)
At 6 mo: 0 vs
2 (P NS)
At 1 y: 0 vs 5
(P NS)
At 3 y: 0 vs 5
(P NS)
Lower fasting C-pep-
tide only in the CsA
group
Higher
MMF and
TAC dose
Vessal
2007
  At 1 y: 1 (high immuno-
logic risk group: 0) vs 6
(P NS)
At 1 y: 1 vs 2,
High immuno-
logic risk group:
0 (P NS)
At 1 y: 6 (4 biopsy
proven) (high immuno-
logic risk group: 1) vs
12 (11 biopsy proven)
(P NS)
0 vs 2 (P NS) Increase in over-
all infections in SM
group (more BK virus
nephropathy, CMV
infection, UTI and
pneumonia) - with
higher levels of TAC
at 1 and 6 months in
this group
 
Malheiro
2009
At 2 y: 2% vs 8%
At 5 y: 2% vs
17% (P NS)
At 2 y: 5% vs 12% (P NS)
At 5 y: 10% vs 25% (P NS)
    At 2 y: 0% vs
8%
At 5 y: 98%
vs 83% (P
NS)
  More fre-
quent
need for
statins
(more pa-
tients with
sirolimus
in SW
group)
Reichman
2011
  8 (17%) at a mean of 33
± 15 mo vs 3 (6.9%) at a
mean of 38 ± 23 mo
  11 (24.4%) at a mean
of 28 ± 18 mo vs 4
(9.3%) at a mean of 38
± 23 mo
Increased risk of rejec-
tion in SW group: HR
2.8, CI 0.89 to 8.81 (P
0.066)
    Increase
risk rejec-
tion. Non
improve-
ment of
risk fac-
tors for
cardiovas-
Table 3.   Data from additional studies analysed  (Continued)
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cular dis-
ease
Luzi 2003           Lower plasma-free
insulin and glucagon
levels and lower
plasma triglyceride
concentration (0.88
± 0.08 mg/mL vs 1.16
± 0.16 mg/mL (P <
0.05)
 
Knight
2005
At 2 y: 1 vs 0
(none due to re-
jection) (P NS)
At 2 y: 1 vs 2
(none due to rejection)
(P NS)
  At 2 y: 0 vs 1 (not con-
firmed by biopsy) (P
NS)
At 2 y: total
0
Better kidney func-
tion beyond 6 mo
 
Fridell
2006
Not censored
for death:
1 vs 0 (P NS)
Not censored for death:
2 vs 0 (P NS)
Total: 0 0 vs 1 1 vs 0    
Rajab
2007
At 1 y: 3 (due to
rejection: 0) vs
2 (due to rejec-
tion: 2) (P NS)
At 1 y: 5 (due to rejec-
tion: 0) vs 15 (due to re-
jection: 7) (P NS)
At 1 y: 9 (all biopsy proven) vs 35
(P < 0.01)
At 1 y: 6 vs 6
(P NS)
Acute rejection low-
er, and greater graD
survival
Less required CsA
(probably due to
sirolimus)
 
Tanchan-
co 2008
  At 6 mo: 1 vs 4 (P NS) At 6 mo: 1 vs 7 (P NS) At 6 mo: 0 vs
2 (P NS)
Less CMV viraemia,
higher eGFR at 6
months
 
Hill 2009 Quote: "not statistically significant between
groups"
At 3 y: 18.7% vs
2.8% (P < 0.05)
At 3 y: 43.3% vs 9.3%
(P < 0.05)
Quote: "not
statistically
significant
between
groups"
  Higher in-
cidence of
rejection
Steroid
avoidance
versus
steroid
mainte-
nance
Lawrecki
2012
  At 1 y: 4% vs 6% (P NS)
At 2 y: 7% vs 12% (P NS)
37% (biopsy proven: 6.5%) vs 36% (biopsy
proven: 15%) (P NS)
At 2 y: 2 vs 0
(P NS)
Improved parame-
ters of HbA1c (at 6,
12 and 24 mo) and
cholesterol total and
 
Table 3.   Data from additional studies analysed  (Continued)
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LDL (at 6, 12 and 24
mo)
Early with-
drawal
versus ear-
ly minimi-
sation ver-
sus main-
tenance
Jepkorir
2012
Not censored
for death:
At 1 y: 3 vs 4 vs
1 (P NS)
At 3 y: 4 vs 7 vs
3 (P NS)
Not censored for death:
At 1 y: 1 vs 2 vs 2 (P NS)
At 3 y: 3 vs 2 vs 4 (P NS)
At 2 y: 7 vs 5 vs
7 (P NS)
At 2 y: 6 vs 3 vs 1 (P NS) At 1 y:
3 vs 1 vs 1 (P
NS)
At 3 y: 4 vs 2
vs 2 (P NS)
Improvement blood
pressure control with
less antihypertensive
medications in ESW
and ESM versus SM.
Lower total (at 1 y)
and LDL cholesterol
levels (at 1 and 2 y) in
ESW
Less severe acute re-
jection at 1 y in ESW
Statistical-
ly higher
HbA1c to
1 year in
ESW
Table 3.   Data from additional studies analysed  (Continued)
ATG - antithymocyte globulin; CMV - cytomegalovirus; CsA - cyclosporin; eGFR - estimated glomerular filtration rate; ESW - early steroid withdrawal; HbA1c- glycated haemoglobin;
MMF - mycophenolate mofetil; mo - month/s; P NS - not significant P value; SA - steroid avoidance; SCr - serum creatinine; SM - steroid maintenance; SW - steroid withdrawal;
TAC - tacrolimus; UTI - urinary tract infection; y - year/s
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A P P E N D I C E S
Appendix 1. Electronic search strategies
 
Database Search terms
CENTRAL 1. MeSH descriptor Pancreas Transplantation, this term only
2. pancrea* next transplant*:ti,ab,kw
3. kidney next pancrea*transplant*:ti,ab,kw
4. (#1 OR #2 OR #3)
5. (avoid* or minim* or free* or withdraw* or spar* or discontinu* or taper* or conversion* or con-
vert*) near25 (predniso* or corticosteroid* or steroid*)
6. (#4 AND #5)
MEDLINE 1. Pancreas Transplantation/
2. Kidney Transplantation/ and Pancreas Transplantation/
3. ("simultaneous kidney" adj2 pancreas).tw.
4. SKP$.tw.
5. or/1-4
6. exp Adrenal Cortex Hormones/
7. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or con-
vert$) adj15 (predniso$ or corticosteroid$ or steroid$)).tw.
8. or/6-7
9. and/5,8
EMBASE 1. exp pancreas transplantation/
2. Kidney Pancreas Transplantation/
3. or/1-2
4. drug withdrawal/
5. exp corticosteroid/
6. ((avoid$ or minim$ or free$ or withdraw$ or spar$ or discontinu$ or taper$ or conversion$ or con-
vert$) adj25 (predniso$ or corticosteroid$ or steroid$)).tw.
7. or/4-6
8. and/3,7
 
 
Appendix 2. Risk of bias assessment tool
 
Potential source of bias Assessment criteria
Yes (low risk of bias): Random number table; computer random number generator; coin tossing;
shuffling cards or envelopes; throwing dice; drawing of lots; minimization (minimization may be
implemented without a random element, and this is considered to be equivalent to being random).
No (high risk of bias): Sequence generated by odd or even date of birth; date (or day) of admission;
sequence generated by hospital or clinic record number; allocation by judgement of the clinician;
by preference of the participant; based on the results of a laboratory test or a series of tests; by
availability of the intervention.
Was there adequate se-
quence generation?
Unclear: Insufficient information about the sequence generation process to permit judgement.
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Yes (low risk of bias): Randomisation method described that would not allow investigator/partici-
pant to know or influence intervention group before eligible participant entered in the study (e.g.
central allocation, including telephone, web-based, and pharmacy-controlled, randomisation; se-
quentially numbered drug containers of identical appearance; sequentially numbered, opaque,
sealed envelopes).
No (high risk of bias): Using an open random allocation schedule (e.g. a list of random numbers); as-
signment envelopes were used without appropriate safeguards (e.g. if envelopes were unsealed or
non-opaque or not sequentially numbered); alternation or rotation; date of birth; case record num-
ber; any other explicitly unconcealed procedure.
Was allocation adequately
concealed?
Unclear: Randomisation stated but no information on method used is available.
Yes (low risk of bias): No blinding, but the review authors judge that the outcome and the outcome
measurement are not likely to be influenced by lack of blinding; blinding of participants and key
study personnel ensured, and unlikely that the blinding could have been broken; either partici-
pants or some key study personnel were not blinded, but outcome assessment was blinded and
the non-blinding of others unlikely to introduce bias.
No (high risk of bias): No blinding or incomplete blinding, and the outcome or outcome measure-
ment is likely to be influenced by lack of blinding; blinding of key study participants and person-
nel attempted, but likely that the blinding could have been broken; either participants or some key
study personnel were not blinded, and the non-blinding of others likely to introduce bias.
Was knowledge of the al-
located interventions ade-
quately prevented during
the study?
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'
Yes (low risk of bias): No missing outcome data; reasons for missing outcome data unlikely to be
related to true outcome (for survival data, censoring unlikely to be introducing bias); missing out-
come data balanced in numbers across intervention groups, with similar reasons for missing data
across groups; for dichotomous outcome data, the proportion of missing outcomes compared with
observed event risk not enough to have a clinically relevant impact on the intervention effect esti-
mate; for continuous outcome data, plausible effect size (difference in means or standardized dif-
ference in means) among missing outcomes not enough to have a clinically relevant impact on ob-
served effect size; missing data have been imputed using appropriate methods.
No (high risk of bias): Reason for missing outcome data likely to be related to true outcome, with
either imbalance in numbers or reasons for missing data across intervention groups; for dichoto-
mous outcome data, the proportion of missing outcomes compared with observed event risk
enough to induce clinically relevant bias in intervention effect estimate; for continuous outcome
data, plausible effect size (difference in means or standardized difference in means) among miss-
ing outcomes enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis
done with substantial departure of the intervention received from that assigned at randomisation;
potentially inappropriate application of simple imputation.
Were incomplete outcome
data adequately addressed?
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'.
Yes (low risk of bias): The study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way;
the study protocol is not available but it is clear that the published reports include all expected out-
comes, including those that were pre-specified (convincing text of this nature may be uncommon).
Are reports of the study free
of suggestion of selective
outcome reporting?
No (high risk of bias): Not all of the study’s pre-specified primary outcomes have been reported; one
or more primary outcomes is reported using measurements, analysis methods or subsets of the da-
ta (e.g. subscales) that were not pre-specified; one or more reported primary outcomes were not
pre-specified (unless clear justification for their reporting is provided, such as an unexpected ad-
verse effect); one or more outcomes of interest in the review are reported incompletely so that they
cannot be entered in a meta-analysis; the study report fails to include results for a key outcome
that would be expected to have been reported for such a study.
  (Continued)
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Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'.
Yes (low risk of bias): The study appears to be free of other sources of bias.
No (high risk of bias): Had a potential source of bias related to the specific study design used;
stopped early due to some data-dependent process (including a formal-stopping rule); had ex-
treme baseline imbalance; has been claimed to have been fraudulent; had some other problem.
Was the study apparently
free of other problems that
could put it at a risk of bias?
Unclear: Insufficient information to permit judgement of ‘Yes’ or ‘No'.
  (Continued)
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D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
The title of the review has been changed from "Steroid avoidance or withdrawal for pancreas and kidney transplants" to "Steroid avoidance
or withdrawal for pancreas and pancreas with kidney transplants", to clarify that studies including pancreas alone have also been included
in the systematic review.
Observational studies have been tabulated and reported in the discussion section of the review, not separately analysed as stated in our
protocol.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
*Kidney Transplantation;  *Pancreas Transplantation;  *Withholding Treatment;  Cohort Studies;  Diabetes Mellitus, Type 1  [surgery];
  GraD Rejection  [*prevention & control];  Immunosuppression  [*adverse eLects];  Kidney Failure, Chronic  [surgery];  Living Donors; 
Randomized Controlled Trials as Topic;  Steroids  [*administration & dosage]  [adverse eLects]
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